LIGAND PHARMACEUTICALS INC 8-K

What Happened
Ligand Pharmaceuticals Incorporated (LGND) announced on April 27, 2026 that it entered into a definitive Agreement and Plan of Merger to acquire XOMA Royalty Corporation. Under the deal, each outstanding XOMA Royalty common share will convert into $39.00 in cash (per share) plus contingent value rights (CVRs) tied to a trust interest in a spun-off RemainCo LLC. The transaction requires XOMA Royalty stockholder approval, Hart-Scott-Rodino clearance, and completion of a holding company reorganization and CVR spin before closing.

Key Details

• Deal date: April 27, 2026; outside termination date: January 26, 2027 (subject to customary termination rights).
• Consideration: $39.00 per share in cash plus CVRs representing contingent payments from a CVR Trust (75% interest in RemainCo LLC will back the CVRs).
• Governance & support: Supporting stockholders (officers, directors and BFV Partners‑affiliated funds) hold ~47% of outstanding shares and signed voting/support agreements to vote in favor.
• Other economics/terms: No financing condition for Ligand; a $40.0 million termination fee is payable by XOMA Royalty in certain circumstances (e.g., if XOMA Royalty accepts a superior proposal under specified conditions). Series X preferred converts into the same Merger Consideration; Series A/B perpetual preferred stock will be redeemed per their terms.

Why It Matters
For investors, this is a definitive acquisition that immediately sets a $39.00-per-share cash value for XOMA Royalty equity while preserving potential upside through CVRs tied to future recoveries from RemainCo LLC (including proceeds related to the Janssen Litigation per the agreement). The transaction hinges on stockholder approval and regulatory clearance, and Ligand’s obligation to close is not subject to financing, which can reduce execution risk. The CVR structure and holding company reorganization create contingent payments rather than all-cash upside, so holders should review the upcoming proxy materials and CVR terms to understand timing, governance and potential payout mechanics.